The enemy's gate is down.

BioNTech, Regeneron’s mRNA Cancer Vaccine Combo Clears Phase II in Melanoma dlvr.it/TBHXcX

Novo Nordisk’s Ozempic Could Help Curb Cigarette Use in Diabetics: Study dlvr.it/TBHXcB

AstraZeneca’s Calquence Aces Phase III CLL Trial, Eyes Fixed-Duration Approval dlvr.it/TBHXbs

Ventyx Ends Development of TYK2 Inhibitor After Phase II Flop in Crohn’s Disease dlvr.it/TBHXZM

Boehringer Buys Nerio Therapeutics for $1.3B to Boost Immuno-Oncology Pipeline dlvr.it/TBDJ8k

WuXi AppTec Hit With Slight Drop in US Revenue as Threat of BIOSECURE Act Looms dlvr.it/TBDJ5M

FDA Flags Safety Risks of Compounded Versions of Novo’s Semaglutide, Reports Hospitalizations dlvr.it/TBCwJ8

AbbVie’s Skyrizi Wins EU Nod for Ulcerative Colitis, Helps to Weather Humira Patent Cliff dlvr.it/TBCwHL

Merck’s Keytruda in Combo With Padcev Granted CHMP Positive Opinion in Urothelial Carcinoma dlvr.it/TBCwDh

Navigating Deaths During Clinical Trials dlvr.it/TBBqrZ

FDA Action Alert: Adaptimmune, Zevra, Lykos and scPharma dlvr.it/TBBqrW

Adaptimmune Gears Up for Potential Approval of First-in-Class Engineered T Cell Therapy dlvr.it/TBBqrS

You Can Buy Meat Grown in a Lab in This Country dlvr.it/TB6ZJM

EU Regulatory Panel Recommends Against Approval of Eisai, Biogen’s Leqembi for Alzheimer’s dlvr.it/TB6DmR

Big Pharma Appears to Be Unfazed by IRA Drug Price Negotiations dlvr.it/TB6Dm5

BMS Gets Q2 Beat, Raises Full-Year Guidance as Cost-Cutting Initiative Continues dlvr.it/TB6Dlh

Roche to Accelerate Development of Obesity Assets from $2.7B Carmot Buy dlvr.it/TB6DlF

FDA Adcomm Calls for Changes in Perioperative Lung Cancer Trials dlvr.it/TB6Dfr